News

A clinical trial demonstrated that bezuclastinib significantly improved symptoms and biomarkers of systemic mastocytosis.

Ultrasensitive duplex sequencing could improve diagnosis of indolent systemic mastocytosis in patients with low variant allele frequencies.

Patients with systemic mastocytosis (SM) showed promising overall response rates to treatment with bezuclastinib, its maker announced.

Some medical specialists lack awareness of systemic mastocytosis (SM) because of its association with various symptoms.

Avapritinib significantly improved overall survival in patients with SM compared to midostaurin or best available therapy.

Patients with systemic mastocytosis (SM) have a different plasma protein profile compared to healthy people.

Preliminary results showed that patients receiving bezuclastinib had better results than patients receiving a placebo in a clinical trial.

RNA-based testing significantly enhanced the detection of KIT mutations, which is critical for diagnosing systemic mastocytosis.

A new study will examine a treatment for patients with systemic mastocytosis with an associated hematologic neoplasm.

Imatinib is a treatment for patients with aggressive SM without the KIT D816V mutation or having unknown KIT mutational status.